Patents by Inventor Eliud Hernandez
Eliud Hernandez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11939337Abstract: Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.Type: GrantFiled: July 13, 2022Date of Patent: March 26, 2024Assignee: UNIVERSITY OF PUERTO RICOInventors: Cornelis P. Vlaar, Suranganie Dharmawardhane Flanagan, Eliud Hernandez-O'Farrill, Linette Castillo-Pichardo
-
Publication number: 20230039997Abstract: Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.Type: ApplicationFiled: July 13, 2022Publication date: February 9, 2023Inventors: Cornelis P. VLAAR, Suranganie DHARMAWARDHANE FLANAGAN, Eliud HERNANDEZ-O'FARRILL, Linette CASTILLO-PICHARDO
-
Patent number: 11446299Abstract: A series of novel EHop-016 derivatives is presented herein via designing and synthesizing compounds that mimics its more favorable “U-shaped” conformation that appears to be critical for inhibitory activity against Rac. Based on modeling studies on EHop-016, compounds with a more rigid structural conformation can mimic this “U-shaped” conformation and would improve the anti-migration activity against metastatic cells. Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases, for instance compounds of formula Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.Type: GrantFiled: July 8, 2020Date of Patent: September 20, 2022Assignee: UNIVERSITY OF PUERTO RICOInventors: Eliud Hernandez-O'Farrill, Cornelis P. Vlaar, Suranganie Dharmawardhane Flanagan, Linette Castillo-Pichardo
-
Patent number: 11390629Abstract: Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperproliferative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.Type: GrantFiled: April 1, 2021Date of Patent: July 19, 2022Assignee: UNIVERSITY OF PUERTO RICOInventors: Cornelis P. Vlaar, Suranganie Dharmawardhane Flanagan, Eliud Hernandez-O'Farrill, Linette Castillo-Pichardo
-
Publication number: 20210261559Abstract: Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperproliferative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.Type: ApplicationFiled: April 1, 2021Publication date: August 26, 2021Inventors: Cornelis P. VLAAR, Suranganie DHARMAWARDHANE FLANAGAN, Eliud HERNANDEZ-O'FARRILL, Linette CASTILLO-PICHARDO
-
Patent number: 10995096Abstract: Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.Type: GrantFiled: March 10, 2020Date of Patent: May 4, 2021Assignee: University of Puerto RicoInventors: Cornelis P. Vlaar, Suranganie Dharmawardhane Flanagan, Eliud Hernandez-O'Farrill, Linette Castillo-Pichardo
-
Patent number: 10947247Abstract: Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.Type: GrantFiled: June 28, 2019Date of Patent: March 16, 2021Assignee: University of Puerto RicoInventors: Cornelis P. Vlaar, Suranganie Dharmawardhane Flanagan, Eliud Hernandez-O'Farrill, Linette Castillo-Pichardo
-
Publication number: 20200352941Abstract: A series of novel EHop-016 derivatives is presented herein via designing and synthesizing compounds that mimics its more favorable “U-shaped” conformation that appears to be critical for inhibitory activity against Rac. Based on modeling studies on EHop-016, compounds with a more rigid structural conformation can mimic this “U-shaped” conformation would improve the anti-migration activity against metastatic cells. Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases, for instance compounds of formula (I) Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.Type: ApplicationFiled: July 8, 2020Publication date: November 12, 2020Inventors: Eliud HERNANDEZ-O'FARRILL, Cornelis P. VLAAR, Suranganie DHARMAWARDHANE FLANAGAN, Linette CASTILLO-PICHARDO
-
Patent number: 10729689Abstract: A series of novel EHop-016 derivatives is presented herein via designing and synthesizing compounds that mimics its more favorable “U-shaped” conformation that appears to be critical for inhibitory activity against Rac. Based on modeling studies on EHop-016, compounds with a more rigid structural conformation can mimic this “U-shaped” conformation would improve the anti-migration activity against metastatic cells. Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases, for instance compounds of formula (I) Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.Type: GrantFiled: October 23, 2018Date of Patent: August 4, 2020Assignee: UNIVERSITY OF PUERTO RICOInventors: Eliud Hernandez-O'Farrill, Cornelis P. Vlaar, Suranganie Dharmawardhane Flanagan, Linette Castillo-Pichardo
-
Publication number: 20200239487Abstract: Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.Type: ApplicationFiled: March 10, 2020Publication date: July 30, 2020Inventors: Cornelis P. VLAAR, Suranganie DHARMAWARDHANE FLANAGAN, Eliud HERNANDEZ-O'FARRILL, Linette CASTILLO-PICHARDO
-
Publication number: 20200010475Abstract: Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.Type: ApplicationFiled: June 28, 2019Publication date: January 9, 2020Inventors: Cornelis P. VLAAR, Suranganie DHARMAWARDHANE FLANAGAN, Eliud HERNANDEZ-O'FARRILL, Linette CASTILLO-PICHARDO
-
Patent number: 10392396Abstract: Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.Type: GrantFiled: May 3, 2018Date of Patent: August 27, 2019Assignee: University of Puerto RicoInventors: Cornelis P. Vlaar, Suranganie Dharmawardhane Flanagan, Eliud Hernandez-O'Farrill, Linette Castillo-Pichardo
-
Publication number: 20190125746Abstract: A series of novel of EHop-016 derivatives is presented herein via designing and synthesizing compounds that mimics its more favorable “U-shaped” conformation that appears to be critical for inhibitory activity against Rac. Based on modeling studies on EHop-016, compounds with a more rigid structural conformation can mimic this “U-shaped” conformation would improve the anti-migration activity against metastatic cells. Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.Type: ApplicationFiled: October 23, 2018Publication date: May 2, 2019Inventors: Eliud HERNANDEZ-O'FARRILL, Cornelis P. VLAAR, Suranganie DHARMAWARDHANE FLANAGAN, Linette CASTILLO-PICHARDO
-
Publication number: 20180251470Abstract: Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.Type: ApplicationFiled: May 3, 2018Publication date: September 6, 2018Inventors: Cornelis P. VLAAR, Suranganie DHARMAWARDHANE FLANAGAN, Eliud HERNANDEZ-O'FARRILL, Linette CASTILLO-PICHARDO
-
Patent number: 9981980Abstract: Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.Type: GrantFiled: April 27, 2017Date of Patent: May 29, 2018Assignee: University of Puerto RicoInventors: Cornelis P. Vlaar, Suranganie Dharmawardhane Flanagan, Eliud Hernandez-O'Farrill, Linette Castillo-Pichardo
-
Publication number: 20170313711Abstract: Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.Type: ApplicationFiled: April 27, 2017Publication date: November 2, 2017Inventors: Cornelis P. VLAAR, Suranganie DHARMAWARDHANE FLANAGAN, Eliud HERNANDEZ-O'FARRILL, Linette CASTILLO-PICHARDO
-
Patent number: 9278956Abstract: A novel inhibitor of Rac activity based on the structure of the established Rac/Rac-GEF inhibitor NSC23766 is discloses. The compound EHop-016, with an IC50 of 1.1 ?M, is a 100-fold more efficient inhibitor of Rac activity than NSC23766. EHop-016 is specific for Rac1 and Rac3 at concentrations ?5 mM. At higher concentrations, EHop-016 inhibits the close homolog Cdc42. In MDA-MB-435 cells, EHop-016 (?5 mM) inhibits the association of the Rac-GEF Vav2 with a nucleotide-free Rac1(G15A), which has a high affinity for activated GEFs. EHop-016 does not affect the association of the Rac-GEF Tiam-1 with Rac1(G15A) at similar concentrations. EHop-016 also inhibits the Rac activity of MDA-MB-231 metastatic breast cancer cells and reduces Rac-directed lamellipodia formation in both cell lines. EHop-016 decreases Rac-downstream effects of p21-activated kinase (PAK)1 activity and directed migration of metastatic cancer cells. At low concentrations (<5 ?M), EHop-016 does not affect cell viability.Type: GrantFiled: November 10, 2014Date of Patent: March 8, 2016Assignee: University of Puerto RicoInventors: Eliud Hernandez, Cornelis Vlaar, Suranganie Dharmawardhane
-
Patent number: 8884006Abstract: A novel inhibitor of Rac activity based on the structure of the established Rac/Rac-GEF inhibitor NSC23766 is discloses. The compound EHop-016, with an IC50 of 1.1 ?M, is a 100-fold more efficient inhibitor of Rac activity than NSC23766. EHop-016 is specific for Rac1 and Rac3 at concentrations ?5 mM. At higher concentrations, EHop-016 inhibits the close homolog Cdc42. In MDA-MB-435 cells, EHop-016 (?5 mM) inhibits the association of the Rac-GEF Vav2 with a nucleotide-free Rac1(G15A), which has a high affinity for activated GEFs. EHop-016 does not affect the association of the Rac-GEF Tiam-1 with Rac1(G15A) at similar concentrations. EHop-016 also inhibits the Rac activity of MDA-MB-231 metastatic breast cancer cells and reduces Rac-directed lamellipodia formation in both cell lines. EHop-016 decreases Rac-downstream effects of p21-activated kinase (PAK)1 activity and directed migration of metastatic cancer cells. At low concentrations (<5 ?M), EHop-016 does not affect cell viability.Type: GrantFiled: September 18, 2012Date of Patent: November 11, 2014Assignee: University of Puerto RicoInventors: Eliud Hernandez, Cornelis Vlaar, Suranganie Dharmawardhane